Cancer Research and Treatment

Original Articles

Validating the Korean Geriatric Assessment Tool in Elderly Multiple Myeloma Patients: A Multicenter Study: Ji Yun Lee, Sang-A Kim, Youngil Koh, Ho-Young Yhim, Gyeong-Won Lee, Chang-Ki Min, Young Rok Do, Hyo Jung Kim, Sung Hwa Bae, Hyeon-Seok Eom, Sung-Hoon Jung, Hyunkyung Park, Seung-Hyun Nam, Ji Hyun Lee, Sung-Hyun Kim, Hyun Jung Lee, Young Seob Park, Soo-Mee Bang; Received January 15, 2025 Accepted February 20, 2025 Published online February 21, 2025; DOI: https://doi.org/10.4143/crt.2025.066 [Accepted]

Abstract PDF: Purpose
This study evaluates the Korean Cancer Study Group Geriatric Score-7 (KG-7) frailty screening tool's effectiveness in elderly multiple myeloma (MM) patients to prevent under and over-treatment.
Materials and Methods
This prospective pilot cohort study included 100 elderly patients aged 70 and older with newly diagnosed MM who had not undergone transplantation from August 2020 to January 2022.
Results
The median age was 77 years, and 73% of patients were classified at International Staging System (ISS) stages 2 or 3. Using a 5-point cutoff on the KG-7 index (non-frail, score ≥ 5; frail, score < 5), 31% were categorized as frail. After a median follow-up of 26.8 months, the 3-year overall survival rate was 73.0%. There was no statistically significant association between any frailty index and the risk of death. However, frail patients defined by the simplified frailty index (HR, 2.49; 95% CI, 1.09–5.95; p=0.030) and by KG-7 (HR, 2.43; 95% CI, 1.03–5.86; p=0.043) had a significantly higher risk of grade 3–4 non-hematologic toxicity, whereas the IMWG definition did not. Over a 24-month tracking period, vulnerability as measured by KG-7 either improved or deteriorated.
Conclusion
The pilot study, which had a limited number of participants, did not demonstrate KG-7’s effectiveness in predicting survival; however, it successfully predicted severe non-hematologic toxicities. We plan to conduct larger studies in elderly MM patients to determine whether KG-7 can help tailor their treatment regimens.

473 View
14 Download

General

Analysis of Cancer Patient Decision-Making and Health Service Utilization after Enforcement of the Life-Sustaining Treatment Decision-Making Act in Korea: Dalyong Kim, Shin Hye Yoo, Seyoung Seo, Hyun Jung Lee, Min Sun Kim, Sung Joon Shin, Chi-Yeon Lim, Do Yeun Kim, Dae Seog Heo, Chae-Man Lim; Cancer Res Treat. 2022;54(1):20-29. Published online April 12, 2021; DOI: https://doi.org/10.4143/crt.2021.131

Abstract PDF PubReader ePub

Purpose
This study aimed to confirm the decision-making patterns for life-sustaining treatment (LST) and analyze medical service utilization changes after enforcement of the Life-Sustaining Treatment Decision-Making Act.
Materials and Methods
Of 1,237 patients who completed legal forms for life-sustaining treatment (hereafter called the LST form) at three academic hospitals and died at the same institutions, 1,018 cancer patients were included. Medical service utilization and costs were analyzed using claims data.
Results
The median time to death from completion of the LST form was three days (range, 0 to 248 days). Of these, 517 people died within two days of completing the document, and 36.1% of all patients prepared the LST form themselves. The frequency of use of the intensive care unit, continuous renal replacement therapy, and mechanical ventilation was significantly higher when the families filled out the form without knowing the patient’s intention. In the top 10% of the medical expense groups, the decision-makers for LST were family members rather than patients (28% patients vs. 32% family members who knew and 40% family members who did not know the patient’s intention).
Conclusion
The cancer patient’s own decision-making rather than the family’s decision was associated with earlier decision-making, less use of some critical treatments (except chemotherapy) and expensive evaluations, and a trend toward lower medical costs.

Citations

Citations to this article as recorded by

Factors Affecting Life-Sustaining Treatment Decisions and Changes in Clinical Practice after Enforcement of the Life-Sustaining Treatment (LST) Decision Act: A Tertiary Hospital Experience in Korea
Yoon Jung Jang, Yun Jung Yang, Hoi Jung Koo, Hye Won Yoon, Seongbeom Uhm, Sun Young Kim, Jeong Eun Kim, Jin Won Huh, Tae Won Kim, Seyoung Seo
Cancer Research and Treatment.2025; 57(1): 280. CrossRef
Characteristics of Life-Sustaining Treatment Decisions: National Data Analysis in South Korea
Jiyeon Choi, Heejung Jeon, Ilhak Lee
Asian Bioethics Review.2024; 16(1): 33. CrossRef
Characteristics and outcomes of patients with do-not-resuscitate and physician orders for life-sustaining treatment in a medical intensive care unit: a retrospective cohort study
Song-I Lee, Ye-Rin Ju, Da Hyun Kang, Jeong Eun Lee
BMC Palliative Care.2024;[Epub] CrossRef
For the Universal Right to Access Quality End-of-Life Care in Korea: Broadening Our Perspective After the 2018 Life-Sustaining Treatment Decisions Act
Hye Yoon Park, Min Sun Kim, Shin Hye Yoo, Jung Lee, In Gyu Song, So Yeon Jeon, Eun Kyung Choi
Journal of Korean Medical Science.2024;[Epub] CrossRef
Comparison of factors influencing the decision to withdraw life-sustaining treatment in intensive care unit patients after implementation of the Life-Sustaining Treatment Act in Korea
Claire Junga Kim, Kyung Sook Hong, Sooyoung Cho, Jin Park
Acute and Critical Care.2024; 39(2): 294. CrossRef
Nurses' engagement in advance care planning practices: A descriptive cross‐sectional study
Sangmin Lee, Naixue Cui, Hyejin Kim
Journal of Clinical Nursing.2024;[Epub] CrossRef
Issues and implications of the life-sustaining treatment decision act: comparing the data from the survey and clinical data of inpatients at the end-of-life process
Eunjeong Song, Dongsoon Shin, Jooseon Lee, Seonyoung Yun, Minjeong Eom, Suhee Oh, Heejung Lee, Jiwan Lee, Rhayun Song
BMC Medical Ethics.2024;[Epub] CrossRef
Development and Feasibility Evaluation of Smart Cancer Care 2.0 Based on Patient-Reported Outcomes for Post-Discharge Management of Patients with Cancer
Jin Ah Kwon, Songsoo Yang, Su-Jin Koh, Young Ju Noh, Dong Yoon Kang, Sol Bin Yang, Eun Ji Kwon, Jeong-Wook Seo, Jin sung Kim, Minsu Ock
Cancer Research and Treatment.2024; 56(4): 1040. CrossRef
Advance Care Planning in South Korea
Yu Jung Kim, Sun-Hyun Kim
Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen.2023; 180: 68. CrossRef
Preferred versus Actual Place of Care and Factors Associated with Home Discharge among Korean Patients with Advanced Cancer: A Retrospective Cohort Study
In Young Hwang, Yohan Han, Min Sun Kim, Kyae Hyung Kim, Belong Cho, Wonho Choi, Yejin Kim, Shin Hye Yoo, Sun Young Lee
Healthcare.2023; 11(13): 1939. CrossRef

7,704 View
205 Download
11 Web of Science
10 Crossref

Validity and Reliability of Korean Version of Simplified Nutritional Appetite Questionnaire in Patients with Advanced Cancer: A Multicenter, Longitudinal Study: So Yeon Oh, Su-Jin Koh, Ji Yeon Baek, Kyung A Kwon, Hei-Cheul Jeung, Kyung Hee Lee, Young-Woong Won, Hyun Jung Lee; Cancer Res Treat. 2019;51(4):1612-1619. Published online April 12, 2019; DOI: https://doi.org/10.4143/crt.2018.505

Abstract PDF PubReader ePub

Purpose
Malnutrition and a loss of muscle mass are frequent in cancer patients and have a negative effect on clinical outcome. Nutrition risk screening aims to increase awareness and allow early recognition and treatment of cancer cachexia. Therefore, screenings should be brief, inexpensive, highly sensitive, and have good specificity. Simplified Nutritional Appetite Questionnaire (SNAQ) is a simple screening tool including four questions, and validated to predict weight loss within 6 months in community-dwelling adults and nursing home residents. Our study aimed to translate the SNAQ into Korean, and to assess the validity and reliability of the translated screening tool in advanced cancer patients.
Materials and Methods
The SNAQ was translated into Korean according to linguistic validation. The internal consistency of the SNAQ was evaluated by Cronbach’s alpha coefficient. Test-retest reliability was evaluated using the intraclass correlation coefficient. Concurrent validity was evaluated by measuring the Pearson’s correlation coefficient between the SNAQ and Mini-Nutritional Assessment (MNA) and Patient-Generated Subjective Global Assessment (PG-SGA).
Results
In the 194 patients included in full analysis set, cancer stage was predominantly metastatic (98.5%), the mean age was 60 years (range, 23 to 81 years), and the mean body mass index was 24 kg/m2 (range, 15.6 to 39.6 kg/m2). According to MNA score ≤ 11, 57 patients (29.4%) were malnourished. The mean score (±standard deviation) of the Korean version of the SNAQ was 13.8±2.5 with a range of 6-19. Cronbach’s alpha coefficient was 0.737, and intraclass correlation coefficient was 0.869. The SNAQ was moderately correlated with MNA (r=0.404, p < 0.001) and PG-SGA (r=–0.530, p < 0.001). A significant weight loss of > 5% of the original bodyweightwithin 6 months occurred in 46 of the 186 patients (24.7%). SNAQ score ≤ 14 predicted > 5% weight loss with a sensitivity of 56.5% and a specificity of 44.3%.
Conclusion
The Korean version of the SNAQ had high validity and reliability. SNAQ is useful for the screening tool for advanced cancer patients. The SNAQ had a limitation to predict impending weight loss in advanced cancer patients.

Citations

Citations to this article as recorded by

Appetite-preserving gastrectomy (APG) for esophagogastric junction cancer: preserving the residual stomach as an endocrine organ
Naoki Hiki, Tadashi Higuchi, Koshi Kumagai, Kota Okuno, Hiroyuki Minoura, Yumi Sato, Shohei Fujita, Hiroki Harada, Motohiro Chuman, Marie Washio, Mikiko Sakuraya, Masahiro Niihara, Yusuke Kumamoto, Takeshi Naitoh, Keishi Yamashita
Gastric Cancer.2025;[Epub] CrossRef
Demographic, clinical and psychological predictors of malnutrition among people with liver cancer
Yumi Kim, Sung Reul Kim, Kyounghae Kim, Su Jong Yu
European Journal of Oncology Nursing.2024; 68: 102497. CrossRef
Therapeutic Potential of Combined Herbal Medicine and Electroacupuncture in Mild Cognitive Impairment Through Cytokine Modulation: An Observational Study
Jung-Hee Jang, Hyeong Joon Jun, ChaYoung Lee, Eunjin Sohn, Ojin Kwon, Dong-Hoon Kang, Muhammad Umar, In Chul Jung, Soo-Jin Jeong
Neuropsychiatric Disease and Treatment.2024; Volume 20: 1331. CrossRef
Reliability and validity of Chinese version of the Simplified Nutritional Appetite Questionnaire (SNAQ) in community-dwelling old people
Gaojie Feng, Xiaohong Sun, Qiumei Wang, Fei Lu, Yuanyuan Li, Yaru Zhou, Xiaohong Liu
Geriatric Nursing.2024; 59: 351. CrossRef
Malnutrition risk screening in adult oncology outpatients: An ASPEN systematic review and clinical recommendations
Elaine B. Trujillo, Kunal C. Kadakia, Cynthia Thomson, Fang Fang Zhang, Alicia Livinski, Kim Pollard, Todd Mattox, Anne Tucker, Valaree Williams, Declan Walsh, Steven Clinton, Aaron Grossberg, Gordon Jensen, Rhone Levin, Jeannine Mills, Anurag Singh, Mere
Journal of Parenteral and Enteral Nutrition.2024; 48(8): 874. CrossRef
Assessment of nutritional status using objective and subjective methods in Greek patients with cancer
Konstantina Vamvakari, Iliana Evangelou, Ioanna Panagiota Kalafati, Michail Kipouros, Rena I. Kosti, Arezina N. Kasti, Odysseas Androutsos
memo - Magazine of European Medical Oncology.2023; 16(3): 200. CrossRef
AIWW: a new nutrition-screening tool for the oncologic population
Yi-Zhong Ge, Zhen-Ming Fu, Qi Zhang, Meng-Meng Song, Guo-Tian Ruan, Xi Zhang, Xiao-Wei Zhang, Xiang-Rui Li, Kang-Ping Zhang, Meng Tang, Xiao-Yue Liu, Ming Yang, Tong Liu, Hai-Lun Xie, He-Yang Zhang, Zi-Wen Wang, Chun-Lei Hu, Shi-Qi Lin, Rui Zhang, Hong-Xi
Science China Life Sciences.2023; 66(8): 1831. CrossRef
Validation of a telephone‐based administration of the simplified nutritional appetite questionnaire
Binh Duong Thai, Jürgen M. Bauer, Annette Eidam, Jane Durga, Stefan Grund, Thomas Mross, Petra Benzinger
Journal of Cachexia, Sarcopenia and Muscle.2023; 14(4): 1848. CrossRef
Faeces from malnourished colorectal cancer patients accelerate cancer progression
Xu Chao, Zhang Lei, Liu Hongqin, Wang Ziwei, Li Dechuan, Du Weidong, Xu Lu, Chen Haitao, Zhang Bo, Ju Haixing, Yao Qinghua
Clinical Nutrition.2022; 41(3): 632. CrossRef
Influence of cognitive function and nurse support on malnutrition risk in nursing home residents
Annamária Pakai, Emese Havasi‐Sántha, Erzsébet Mák, Orsolya Máté, Dorina Pusztai, Noémi Fullér, Miklós Zrínyi, András Oláh
Nursing Open.2021; 8(4): 1805. CrossRef
Effectiveness of Oral Nutritional Supplements on Older People with Anorexia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Mengqi Li, Si Zhao, Shuang Wu, Xiufen Yang, Hui Feng
Nutrients.2021; 13(3): 835. CrossRef
Loss of appetite in patients with amyotrophic lateral sclerosis is associated with weight loss and anxiety/depression
Yajun Wang, Shan Ye, Lu Chen, Lu Tang, Dongsheng Fan
Scientific Reports.2021;[Epub] CrossRef
Efficacy and Tolerability of Cyproheptadine in Poor Appetite: A Multicenter, Randomized, Double-blind, Placebo-controlled Study
Sue Youn Kim, Jae Moon Yun, Ji-Won Lee, Young Gyu Cho, Kyung-Hwan Cho, Yong Gyu Park, Belong Cho
Clinical Therapeutics.2021; 43(10): 1757. CrossRef
Development of Korean Frailty Index for Primary Care (KFI-PC) and Its Criterion Validity
Chang Won Won, Yunhwan Lee, Seoyoon Lee, Miji Kim
Annals of Geriatric Medicine and Research.2020; 24(2): 125. CrossRef
The Simplified Nutritional Appetite Questionnaire (SNAQ) as a Screening Tool for Risk of Malnutrition: Optimal Cutoff, Factor Structure, and Validation in Healthy Community-Dwelling Older Adults
Sabrina Lau, Kalene Pek, Justin Chew, Jun Pei Lim, Noor Hafizah Ismail, Yew Yoong Ding, Matteo Cesari, Wee Shiong Lim
Nutrients.2020; 12(9): 2885. CrossRef

8,382 View
208 Download
17 Web of Science
15 Crossref

Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancers: So Jeong Lee, Cheong-Soo Hwang, Young-Keum Kim, Hyun Jung Lee, Sang-Jeong Ahn, Nari Shin, Jung Hee Lee, Dong Hoon Shin, Kyung Un Choi, Do Youn Park, Chang Hun Lee, Gi Young Huh, Mi Young Sol, Hee Jin Lee, Gyungyub Gong, Jee Yeon Kim, Ahrong Kim; Cancer Res Treat. 2017;49(2):313-321. Published online July 7, 2016; DOI: https://doi.org/10.4143/crt.2016.098

Abstract PDF PubReader ePub

Purpose
The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been determined in breast cancers. Interferons can affect T-cell activity through direct and indirect mechanisms. Myxovirus resistance A (MxA) is an excellent marker of interferon activity. Here,we evaluated TILs and MxA expression in human epidermal growth factor receptor 2 (HER2)–positive breast cancers.
Materials and Methods
Ninety cases of hormone receptor (HR)+/HER2+ tumors and 78 cases of HR–/HER2+ tumors were included. The TILs level was assessed using hematoxylin and eosin–stained full face sections, and MxA expressionwas evaluated by immunohistochemistrywith a tissue microarray.
Results
MxA protein expression was significantly higher in tumors with high histologic grade (p=0.023) and high levels of TILs (p=0.002). High levels of TILs were correlated with high histological grade (p=0.001), negative lymphovascular invasion (p=0.007), negative lymph node metastasis (p=0.007), absence of HR expression (p < 0.001), abundant tertiary lymphoid structures (TLSs) around ductal carcinoma in situ (p=0.018), and abundant TLSs around the invasive component (p < 0.001). High levels of TILs were also associated with improved disease-free survival, particularly in HR–/HER2+ breast cancers. However, MxA was not a prognostic factor.
Conclusion
High expression of MxA in tumor cells was associated with high levels of TILs in HER2-positive breast cancers. Additionally, a high level of TILs was a prognostic factor for breast cancer, whereas the level of MxA expression had no prognostic value.

Citations

Citations to this article as recorded by

Multi-resolution deep learning characterizes tertiary lymphoid structures and their prognostic relevance in solid tumors
Mart van Rijthoven, Simon Obahor, Fabio Pagliarulo, Maries van den Broek, Peter Schraml, Holger Moch, Jeroen van der Laak, Francesco Ciompi, Karina Silina
Communications Medicine.2024;[Epub] CrossRef
The roles of tertiary lymphoid structures in chronic diseases
Yuki Sato, Karina Silina, Maries van den Broek, Kiyoshi Hirahara, Motoko Yanagita
Nature Reviews Nephrology.2023; 19(8): 525. CrossRef
NFIC1 suppresses migration and invasion of breast cancer cells through interferon-mediated Jak-STAT pathway
Jing Zhang, Mingyue Fan, Chanjuan Jin, Zhaoying Wang, Yutong Yao, Yueru Shi, Xin Hu, Youzhong Wan
Archives of Biochemistry and Biophysics.2022; 727: 109346. CrossRef
Low MxA Expression Predicts Better Immunotherapeutic Outcomes in Glioblastoma Patients Receiving Heat Shock Protein Peptide Complex 96 Vaccination
Yi Wang, Chunzhao Li, Xiaohan Chi, Xijian Huang, Hua Gao, Nan Ji, Yang Zhang
Frontiers in Oncology.2022;[Epub] CrossRef
Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer
Abrar I. Aljohani, Chitra Joseph, Sasagu Kurozumi, Omar J. Mohammed, Islam M. Miligy, Andrew R. Green, Emad A. Rakha
Breast Cancer Research and Treatment.2020; 181(3): 541. CrossRef
Expression of Immunoproteasome Subunit LMP7 in Breast Cancer and Its Association with Immune-Related Markers
Miseon Lee, In Hye Song, Sun-Hee Heo, Young-Ae Kim, In Ah Park, Won Seon Bang, Hye Seon Park, Gyungyub Gong, Hee Jin Lee
Cancer Research and Treatment.2019; 51(1): 80. CrossRef
Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit
Jiawei Chen, Chongxian Hou, Peng Wang, Yong Yang, Dong Zhou
World Neurosurgery.2019; 132: e76. CrossRef
Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value
Ahrong Kim, So Jeong Lee, Young Keum Kim, Won Young Park, Do Youn Park, Jee Yeon Kim, Chang Hun Lee, Gyungyub Gong, Gi Yeong Huh, Kyung Un Choi
Scientific Reports.2017;[Epub] CrossRef

11,845 View
274 Download
8 Web of Science
8 Crossref

A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer: Hyun Jung Lee, Dae-Seog Heo, Joo-Youn Cho, Sae-Won Han, Hye-Jung Chang, Hyeon-Gyu Yi, Tae-Eun Kim, Se-Hoon Lee, Do-Youn Oh, Seock-Ah Im, In-Jin Jang, Yung-Jue Bang; Cancer Res Treat. 2014;46(3):234-242. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.234

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, and recommended phase II dose of an oral drug composed of paclitaxel and HM30181A, which is an inhibitor of P-glycoprotein, in patients with advanced cancers. Materials and Methods Patients with advanced solid tumors received standard therapy were given the study drug at escalating doses, using a 3+3 design. The study drug was orally administered on days 1, 8, and 15, with a 28-day cycle of administration. The dose of paclitaxel was escalated from 60 to 420 mg/m², and the dose of HM30181A was escalated from 30-210 mg/m². Results A total of twenty-four patients were enrolled. Only one patient experienced a doselimiting toxicity—a grade 3 neutropenia that persisted for more than 2 weeks, at 240 mg/m² of paclitaxel. MTD was not reached. The maximum plasma concentration was obtained at a dose level of 300 mg/m² and the area under the curve of plasma concentration- time from 0 to the most recent plasma concentration measurement of paclitaxel was reached at a dose level of 420 mg/m². The absorption of paclitaxel tends to be limited at doses that exceed 300 mg/m². The effective plasma concentration of paclitaxel was achieved at a dose of 120 mg/m². Responses of 23 patients were evaluated; 8 (34.8%) had stable disease and 15 (65.2%) had progressive disease. Conclusion The study drug appears to be well tolerated, and the effective plasma concentration of paclitaxel was achieved. The recommended phase II dose for oral paclitaxel is 300 mg/m².

Citations

Citations to this article as recorded by

Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay
Zofia M. Komar, Nicole S. Verkaik, Ahmed Dahmani, Elodie Montaudon, Roland Kanaar, Adriaan B. Houtsmuller, Agnes Jager, Elisabetta Marangoni, Dik C. van Gent
npj Breast Cancer.2025;[Epub] CrossRef
Screening of photosensitizers-ATP binding cassette (ABC) transporter interactions in vitro
Shruti Vig, Payal Srivastava, Idrisa Rahman, Renee Jaranson, Anika Dasgupta, Robert Perttilä, Petteri Uusimaa, Huang-Chiao Huang
Cancer Drug Resistance.2024;[Epub] CrossRef
Pharmacokinetic modulation of substrate drugs via the inhibition of drug-metabolizing enzymes and transporters using pharmaceutical excipients
Min-Koo Choi, Jihoon Lee, Im-Sook Song
Journal of Pharmaceutical Investigation.2023; 53(1): 1. CrossRef
Redox-responsive drug-inhibitor conjugate encapsulated in DSPE-PEG2k micelles for overcoming multidrug resistance to chemotherapy
Penghui Wang, Yuling Wang, Xuelin Xia, Wei Huang, Deyue Yan
Biomaterials Science.2023; 11(12): 4335. CrossRef
Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study
Ming-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, Yen-Shen Lu, Her-Shyong Shiah, Christopher G. C. A. Jackson, Noelyn Hung, Jianguo Zhi, David L. Cutler, Rudolf Kwan, Douglas Kramer, Wing-Kai Chan, Albert Qin, Kuan-Chiao Tseng, Cheung Tak Hung, Tsu-Yi Chao
Therapeutic Advances in Medical Oncology.2023;[Epub] CrossRef
Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors
Jimmy He, Christopher G. C. A. Jackson, Sanjeev Deva, Tak Hung, Katriona Clarke, Eva Segelov, Tsu‐Yi Chao, Ming‐Shen Dai, Hsien‐Tang Yeh, Wen Wee Ma, Douglas Kramer, Wing‐Kai Chan, Rudolf Kwan, David Cutler, Jay Zhi
CPT: Pharmacometrics & Systems Pharmacology.2022; 11(7): 867. CrossRef
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies
Wen Wee Ma, Jenny J. Li, Nilofer S. Azad, Elaine T. Lam, Jennifer R. Diamond, Grace K. Dy, Mateusz Opyrchal, Jay Zhi, Douglas Kramer, Wing-Kai Chan, David Cutler, Rudolf Kwan, Alex A. Adjei, Antonio Jimeno
Cancer Chemotherapy and Pharmacology.2022; 90(1): 7. CrossRef
Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistance
Hai Wang, Yutong Liang, Yue Yin, Jie Zhang, Wen Su, Alisa M. White, Bin Jiang, Jiangsheng Xu, Yuntian Zhang, Samantha Stewart, Xiongbin Lu, Xiaoming He
Nature Communications.2021;[Epub] CrossRef
The Intravenous to Oral Switch of Taxanes: Strategies and Current Clinical Developments
Marit A C Vermunt, Andries M Bergman, Eric van der Putten, Jos H Beijnen
Future Oncology.2021; 17(11): 1379. CrossRef
Itraconazole synergistically increases therapeutic effect of paclitaxel and 99mTc-MIBI accumulation, as a probe of P-gp activity, in HT-29 tumor-bearing nude mice
Mahdi Ghadi, Seyed Jalal Hosseinimehr, Fereshteh Talebpour Amiri, Alireza Mardanshahi, Zohreh Noaparast
European Journal of Pharmacology.2021; : 173892. CrossRef
Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor
Michael P. Smolinski, Sameer Urgaonkar, Laura Pitzonka, Murray Cutler, GwanSun Lee, Kwee Hyun Suh, Johnson Y. N. Lau
Journal of Medicinal Chemistry.2021; 64(7): 3677. CrossRef
Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study
Christopher G. C. A. Jackson, Tak Hung, Eva Segelov, Paula Barlow, Hans Prenen, Blair McLaren, Noelyn Anne Hung, Katriona Clarke, Tsu‐Yi Chao, Ming‐Shen Dai, Hsien‐Tang Yeh, David L. Cutler, Douglas Kramer, Jimmy He, Jay Zhi, Wing‐Kai Chan, Rudolf Kwan, S
British Journal of Clinical Pharmacology.2021; 87(12): 4670. CrossRef
Further enhanced dissolution and oral bioavailability of docetaxel by coamorphization with a natural P-gp inhibitor myricetin
Yuanfeng Wei, Shengyan Zhou, Tianyun Hao, Jianjun Zhang, Yuan Gao, Shuai Qian
European Journal of Pharmaceutical Sciences.2019; 129: 21. CrossRef
DHP23002 as a next generation oral paclitaxel formulation for pancreatic cancer therapy
Eunseo Jang, Minhee Son, Junhee Jang, In-Hyun Lee, Sol Kim, Taejun Kwon, Yong-hyun Jeon, Woo-Suk Koh, Kil-Soo Kim, Sang Kyoon Kim, Sumitra Deb
PLOS ONE.2019; 14(11): e0225095. CrossRef
Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles
Marco C. Cavaco, Carolina Pereira, Bruna Kreutzer, Luis F. Gouveia, Beatriz Silva-Lima, Alexandra M. Brito, Mafalda Videira
European Journal of Pharmaceutics and Biopharmaceutics.2017; 110: 76. CrossRef
Effect of HM30181 mesylate salt-loaded microcapsules on the oral absorption of paclitaxel as a novel P-glycoprotein inhibitor
Jin Cheul Kim, Kyeong Soo Kim, Dong Shik Kim, Sung Giu Jin, Dong Wuk Kim, Yong Il Kim, Jae-Hyun Park, Jong Oh Kim, Chul Soon Yong, Yu Seok Youn, Jong Soo Woo, Han-Gon Choi
International Journal of Pharmaceutics.2016; 506(1-2): 93. CrossRef
Direct in vivo evidence on the mechanism by which nanoparticles facilitate the absorption of a water insoluble, P-gp substrate
Ramesh Soundararajan, Kenji Sasaki, Lisa Godfrey, Uchechukwu Odunze, Nancy Fereira, Andreas Schätzlein, Ijeoma Uchegbu
International Journal of Pharmaceutics.2016; 514(1): 121. CrossRef

17,359 View
172 Download
18 Web of Science
17 Crossref

Correspondence

Reply to Commentary on "A Case of Erdheim-Chester Disease with Asymptomatic Renal Involvement": Hyun Jung Lee, Tae Min Kim; Cancer Res Treat. 2012;44(4):280-280. Published online December 31, 2012; DOI: https://doi.org/10.4143/crt.2012.44.4.280

Abstract PDF PubReader ePub

No abstract available.

Citations

Citations to this article as recorded by

Enfermedad de Erdheim-Chester: fractura patológica de húmero izquierdo
Luis Gómez, Camilo Soto, Felipe Criollo, Óscar Messa, Ricardo Romo, Irene Patrón
Revista Colombiana de Cancerología.2014; 18(3): 143. CrossRef

8,567 View
53 Download
1 Crossref

Case Report

A Case of Erdheim-Chester Disease with Asymptomatic Renal Involvement: Hyun Jung Lee, Kyoung Yul Lee, Dong-Yeop Shin, Yun Gyoo Lee, Se Youn Choi, Kyung Chul Moon, Il-Kyu Han, Tae Min Kim; Cancer Res Treat. 2012;44(2):146-150. Published online June 30, 2012; DOI: https://doi.org/10.4143/crt.2012.44.2.146

Abstract PDF PubReader ePub

Erdheim-Chester disease is a rare non-Langerhans-cell histiocytosis involving bones and multiple organs. Its clinical course can vary, from an asymptomatic state to a fatal disease, with renal involvement being a common cause of death. A 41-year-old man presented with a 10-month history of bilateral lower limb pain. Left perirenal soft-tissue infiltration had been found incidentally two years earlier. No progression of the lesion or deterioration of renal function was observed for a period of two years. At admission, plain radiography and magnetic resonance imaging of the patient's lower limbs showed patchy osteosclerosis. Biopsy of the tibia revealed histiocytic infiltration, which was found to be positive for CD68 and negative for CD1a. This report describes an unusual case of Erdheim-Chester disease involving a stationary course of disease with no specific treatment for a long period of time.

Citations

Citations to this article as recorded by

Radiological assessment of extremity bone involvement in Erdheim-Chester disease: a systematic review of case reports
Arash Azhideh, Alireza Pouramini, Sara Haseli, Elahe Abbaspour, Gita Karande, Fatemeh Kafi, Majid Chalian
Skeletal Radiology.2024;[Epub] CrossRef
Erdheim–Chester Disease Involving the Biliary System and Mimicking Immunoglobulin G4-Related Disease: A Case Report
Hyuk Gi Hong, Yong Eun Chung, June Park, Yeo Eun Kim
Journal of the Korean Society of Radiology.2023; 84(3): 757. CrossRef
The role of nuclear medicine in the diagnosis of Erdheim–chester disease. A series of clinical observations
A. S. Krylov, A. D. Ryzhkov, A. A. Odzharova, Ya. A. Shchipakhina, E. E. Stanyakina, A. A. Martinovich, K. D. Ilkaev, A. M. Stroganova, S. L. Dranko, O. P. Bliznyukovv, A. V. Kuzin, P. A. Zeynalova, A. A. Semenova, M. B. Dolgushin
Oncohematology.2020; 15(1): 28. CrossRef
Erdheim–Chester disease. Literature review and clinical case
A. S. Krylov, M. B. Dolgushin, A. D. Ryzhkov, A. A. Odzharova, Ya. A. Shchipakhina, E. A. Sushentsov, O. P. Bliznyukov, S. M. Kaspshik, A. A. Martinovich, A. M. Stroganova, S. L. Dranko, P. A. Zeynalova, T. T. Valiev
Oncohematology.2020; 15(2): 61. CrossRef
Magnetic Resonance Imaging of Perirenal Pathology
James F. Glockner, Christine U. Lee
Canadian Association of Radiologists Journal.2016; 67(2): 149. CrossRef
Erdheim-Chester Disease with Perirenal Masses Containing Macroscopic Fat Tissue
Jonghyun Byeon, Kyung Ah Kim, Seong Su Hwang, Soo Youn Park, Hyun A Kim
Journal of the Korean Society of Radiology.2015; 72(2): 143. CrossRef
Urologic Manifestations of Erdheim-Chester Disease
Daniel A. Yelfimov, Deborah J. Lightner, Matthew K. Tollefson
Urology.2014; 84(1): 218. CrossRef
Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series
Roei D Mazor, Mirra Manevich-Mazor, Anat Kesler, Orna Aizenstein, Iris Eshed, Ronald Jaffe, Yakov Pessach, Ilan Goldberg, Eli Sprecher, Iris Yaish, Alexander Gural, Chezi Ganzel, Yehuda Shoenfeld
BMC Medicine.2014;[Epub] CrossRef
A Rare Cause of Late-Onset Cerebellar Ataxia: Erdheim–Chester Disease
Senthilkumar V. Shanmugam, Madhan Kolappan, Mamta Garg, Winston J. Rennie, Peter Furness, Yusuf A. Rajabally
The Cerebellum.2013; 12(4): 593. CrossRef
Reply to Commentary on "A Case of Erdheim-Chester Disease with Asymptomatic Renal Involvement"
Hyun Jung Lee, Tae Min Kim
Cancer Research and Treatment.2012; 44(4): 280. CrossRef
Commentary on "A Case of Erdheim-Chester Disease with Asymptomatic Renal Involvement"
Gioacchino Li Cavoli
Cancer Research and Treatment.2012; 44(4): 279. CrossRef

15,685 View
77 Download
11 Crossref

First
Prev
Page of 1
Next
Last

Search